Medifast Inc
MED Financials — Income Statement, Margins & Balance Sheet
Revenue, net income, margins, cash and debt for MED, built from reported filings and live market data — the three statements condensed into what actually moves the valuation.
MED Income Statement (TTM)
- Net income (TTM)
- -$20.02M
- EPS (TTM)
- $-1.82
- Gross margin
- 69.2%
- Operating margin
- -6.2%
- Net margin
- -8.1%
- Revenue growth
- -27.6%
MED Revenue vs Net Income by Quarter
Light bars are revenue, solid bars are net income. The gap between them is the cost of running the business — when it narrows, margins are expanding.
MED Financial Results by Period
The last 12 reported periods for MED, most recent first.
| Period | Revenue | Net income | Net margin | EPS |
|---|---|---|---|---|
| Q1 2026 | $76.04M | -$2.12M | -2.8% | $-0.19 |
| Q4 2025 | $75.10M | -$18.12M | -24.1% | $-1.65 |
| Q3 2025 | $89.41M | -$2.26M | -2.5% | $-0.20 |
| Q2 2025 | $105.56M | $2.48M | 2.3% | $0.22 |
| Q1 2025 | $115.73M | -$772000 | -0.7% | $-0.07 |
| Q4 2024 | $119.00M | $801000 | 0.7% | $0.07 |
| Q3 2024 | $140.16M | $1.13M | 0.8% | $0.11 |
| Q2 2024 | $168.56M | $163000 | 0.1% | $0.01 |
| Q1 2024 | $174.74M | $8.32M | 4.8% | $0.76 |
| Q4 2023 | $191.01M | $6.04M | 3.2% | $0.55 |
| Q3 2023 | $235.87M | $23.13M | 9.8% | $2.12 |
| Q2 2023 | $296.19M | $30.28M | 10.2% | $2.76 |
MED Balance Sheet & Cash Generation
Cash, debt, share count and free cash flow — the inputs that decide whether MED can fund growth without diluting shareholders.
- Cash
- —
- Total debt
- —
- Net cash / (debt)
- —
- Shares outstanding
- 0.01B
- Free cash flow
- —
- FCF yield
- —
- Market cap
- $131.60M
- Price / sales
- 0.38x
Financials vs Valuation & Market Positioning
The statements tell you what the business earns; the multiples and Z-Score tell you what the market is currently charging for it.
- Trailing P/E
- —
- Forward P/E
- —
- EPS growth
- —
- Revenue growth
- -27.6%
How This MED Financial Data Is Built
Revenue, net income and EPS come from MED's reported filings through live ZCoreAI market endpoints. Trailing twelve-month figures sum the last four reported quarters, and net margin per period is net income divided by revenue for that same period. Gross and operating margins are taken from the reported profitability block.
Cash, debt and share count come from the latest published balance sheet; where a figure is absent, free cash flow is approximated from reported net income and shares are derived from market cap divided by price. Price to sales, FCF yield and the multiples use the live quote, so they update on every page load. Nothing here is investment advice.
MED Financials FAQ
How much revenue does MED generate?
MED generated roughly $346.10M of revenue over the trailing twelve months, summed from the last four reported quarters.
Is MED profitable?
MED runs a -8.1% net margin, equal to -$20.02M of trailing net income.
Does MED have too much debt?
Balance sheet detail for MED is not published in the current dataset.
What is MED's free cash flow?
A free cash flow figure for MED is not available from the current dataset.
Where does ZCoreAI get MED financial data?
Revenue, net income, EPS, margins and balance sheet items come from live ZCoreAI market endpoints sourced from company filings, refreshed on every page load.
Quarterly EPS history, revenue trend and growth for MED.
Trailing and forward multiples, PEG and earnings yield for MED.
DCF fair value, price prediction and signal targets for MED.
Live chart, fundamentals and valuation context for MED.
Data refreshed from live ZCoreAI market endpoints. Informational only — not investment advice.